Adage Capital Partners’s Soleno Therapeutics SLNO Stock Holding History

Adage Capital Partners’s Portfolio SLNO Stock Details SLNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-1,401,576	Closed	-$94.7M	–	1005
2025 Q3	$94.7M	Sell	1,401,576 -2,174,388	-61%	-$161M	0.15%	133
2025 Q2	$300M	Sell	3,575,964 -816,732	-19%	-$61.1M	0.5%	28
2025 Q1	$314M	Buy	4,392,696 +1,616,720	+58%	+$78.7M	0.58%	27
2024 Q4	$125M	Sell	2,775,976 -546,170	-16%	-$28.3M	0.22%	87
2024 Q3	$168M	Buy	3,322,146 +468,052	+16%	+$22.4M	0.3%	58
2024 Q2	$116M	Buy	2,854,094 +910,574	+47%	+$38.6M	0.22%	89
2024 Q1	$83.2M	Buy	1,943,520 +116,706	+6%	+$5.28M	0.16%	133
2023 Q4	$73.5M	Buy	1,826,814 +499,814	+38%	+$14.2M	0.15%	147
2023 Q3	$39.2M	Buy	+1,327,000	New	+$8.03M	0.09%	241

Other funds holding SLNO

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Adage Capital Partners's SLNO Position: Q4 2025 in Review

Adage Capital Partners sold out of Soleno Therapeutics (SLNO) in Q4 2025, closing a stake of 1,401,576 shares — an estimated $94.7M sold.

Adage Capital Partners first reported a position in SLNO in Q3 2023 and held it in 9 quarters. The position peaked at $314M in Q1 2025. 248 funds tracked by Wall St. Rank hold SLNO as of Q4 2025.

Adage Capital Partners reported no remaining Soleno Therapeutics position as of Q4 2025 after selling out during the quarter.
Adage Capital Partners sold 1,401,576 Soleno Therapeutics shares in Q4 2025, an estimated $94.7M.
Adage Capital Partners first reported a position in Soleno Therapeutics in Q3 2023 and held it in 9 quarters.
Adage Capital Partners's Soleno Therapeutics position peaked at $314M in Q1 2025.
248 funds tracked by Wall St. Rank held Soleno Therapeutics as of Q4 2025.

Based on Adage Capital Partners's 13F filing for Q4 2025, filed 17 Feb 2026.